SQZ Biotechnologies (SQZ) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies (NYSE: SQZ) is a clinical‐stage biotechnology company that specializes in the development of novel cell therapies for oncology and infectious diseases. The company’s proprietary Cell Squeeze® platform uses a microfluidic device to temporarily open pores in cell membranes, enabling the delivery of proteins, peptides, mRNA and other cargo directly into the cytosol without relying on viral or chemical vectors. This approach aims to generate potent antigen‐presenting cells and engineered T cells while reducing manufacturing complexity and safety concerns common to viral‐based methods.

The company’s pipeline includes both oncology and infectious disease programs. Key programs include an HPV‐targeted antigen‐presenting cell therapy designed to stimulate a robust immune response against HPV16‐associated malignancies and a series of CAR‐T candidates engineered via the Cell Squeeze platform for solid tumors. SQZ Biotechnologies has collaborations with academic institutions and biopharmaceutical partners to advance preclinical and clinical studies, with the goal of demonstrating proof‐of‐concept in a range of indications.

Founded in 2014 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies completed its transition to a publicly traded company in 2021 through a merger with a special purpose acquisition company. The company operates a dedicated manufacturing facility in the Greater Boston area and continues to expand research partnerships to validate its platform across multiple cell therapy modalities. As SQZ advances its lead candidates through regulatory filings and clinical trials, it aims to redefine the delivery and engineering of cell‐based medicines for patients worldwide.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.25 to $3.56
• Volume: 900 shs
• Average Volume: 455,220 shs
• Market Capitalization: $825.75 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZ Stock Analysis - Frequently Asked Questions

How have SQZ shares performed this year?

SQZ Biotechnologies' stock was trading at $0.03 at the beginning of 2025. Since then, SQZ stock has decreased by 6.7% and is now trading at $0.0280.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) posted its earnings results on Wednesday, November, 10th. The company reported ($8.00) earnings per share for the quarter, missing the consensus estimate of ($5.60) by $2.40. The firm had revenue of $4.76 million for the quarter, compared to analysts' expectations of $11.64 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 119.83% and a negative net margin of 369.96%.

When did SQZ Biotechnologies' stock split?

SQZ Biotechnologies shares reverse split on the morning of Friday, July 7th 2023.The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did SQZ Biotechnologies IPO?

SQZ Biotechnologies (SQZ) raised $75 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SQZ Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Transportation
• Current Symbol: NYSE:SQZ
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 1,620
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.46 million
• Net Margins: -369.96%
• Pretax Margin: -408.99%
• Return on Equity: -119.83%
• Return on Assets: -59.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: $18.16 million
• Price / Sales: 0.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 29,491,000
• Free Float: 24,772,000
• Market Cap: $825.75 thousand
• Optionable: Not Optionable
• Beta: 2.34